In pharma, here are the top 10 news stories of the year so far, based on web traffic.
Less than two weeks after losing longtime acquisition target Allergan--which happily sold itself to Actavis to dodge Valeant's hostile bid and the R&D cuts it feared would come along with it--the Canadian pharma is talking up the productivity of its own labs.
The crowd is already assembling to watch Sanofi's upcoming rollout of Afrezza, the inhaled insulin developed by MannKind.
Targeted drugs, personalized medicine, stratified therapy--whatever you call it, using biomarkers to identify particular patients for particular drugs has been hailed as a boon for patients and a savvy strategy for pharma.
Forget the odds on Thanksgiving Day football games. What's your bet on Pfizer lodging another bid for AstraZeneca?
Here's some good news for Lundbeck in an otherwise bleak week: The U.K.'s cost watchdog has endorsed its alcohol-dependence treatment, Selincro.
Some good news for emerging-market ambitions: China is backpedaling on price caps. After shortages prompted the government to ease up on certain price controls earlier this year, officials are now preparing to lift the price controls as early as Jan. 1.
When Biogen Idec reported last month that a patient taking its hot multiple sclerosis pill Tecfidera had developed a rare brain infection and died, the drugmaker said it believed the safety profile of the drug remained solid. Perhaps so, but the FDA has decided the death was important enough to add a description of it on Tecfidera labels.
With the EU approval of COPD med Duaklir, AstraZeneca is getting exactly what it wanted when it sealed a deal for Almirall's respiratory portfolio earlier this month. The only problem? Calling the market crowded is an understatement.
AstraZeneca and Ranbaxy Laboratories have been unable to wiggle out of a pay-for-delay case that said they colluded to keep generics of AstraZeneca's blockbuster heart medicine off the market until its patent expired in May 2014. The drug is still not on the market but at this point it is not because of backroom deals but because of FDA oversight and Ranbaxy's drug testing mess ups.
Turns out it may not be just Bayer's plastics business that's on its way out the door. The company is reportedly exploring a sale of its diabetes device business as it rides pharma's slim-down wave.
When Takeda Pharmaceutical faced the patent-cliff blues, it brought in Christophe Weber as president and COO to engineer a revamp. And true to his mission, Weber unveiled a new org chart in September, along with a fresh set of top managers.
Novo Nordisk says it has reorganized its executive team, with EVP Lise Kingo making an exit and her duties divvied up among the company's remaining top execs.
Actavis has a lot to do as it works to bring new acquisition Allergan into the fold. And finding ways to grow the California company's products in China is high on the list.
Once Bayer raises the billions it anticipates from an IPO of its plastics business, it plans to pay off debt. But after that? Expect some OTC acquisitions, the company's CEO says.
The U.K.'s cost gatekeeper is notoriously strict when it comes to approving drugs, shooting down meds based on strict cost-effectiveness standards or saddling them with restrictions. But cancer drugs could face the toughest road ahead, as a new report shows that the National Institute of Health and Care Excellence is less likely to green-light the meds compared to other classes of drugs.
AstraZeneca has been touting its pipeline full of promising products as a reason it will return to growth by 2017 and has no need to hook up with Pfizer. As if to put an exclamation point on that declaration, the company says it will kick off a U.S. expansion that will add 300 jobs so it can realize that potential.
Rising cancer drug prices aren't just alarming to payers. They're squeezing oncologists, too, at a time when doctors are paid less to administer drugs--to the point where they're selling out to hospitals.
You breach your company's code of conduct, you're out of the CEO's chair--at least, if you're Lundbeck CEO Ulf Wiinberg. The Danish drugmaker's chief is packing his bags after failing to follow procedures on stock ownership.